SOURCE: SpectraScience, Inc.

SpectraScience, Inc.

May 24, 2016 09:15 ET

SpectraScience Announces First Use of WavSTAT4 Optical Biopsy System in Spain

SAN DIEGO, CA--(Marketwired - May 24, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that physician training has been completed for the first group of physicians utilizing the WavSTAT4 Optical Biopsy SystemR in Barcelona, Spain. Dr. Ramon Abad and his team at Hospital CIMA Sanitas in Barcelona are the first team in Spain to be trained on the system. Training was completed at the hospital on May 13th.

"We are pleased to be working with a team as talented and forward-thinking as Dr. Abad's. They are among the most highly regarded gastroenterologists in Europe," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "Our system is designed to complement the capabilities of the clinician and does not require any change to the current colonoscopy procedure. The WavSTAT Optical Biopsy System provides an accurate diagnosis in about 1 second."

"The system is fast and easy to use," said Dr. Ramon Abad, Chief of Gastroenterology at Hospital CIMA Sanitas. "We found that with just a few cases we felt extremely comfortable with the device. We feel this diagnostic tool has a great deal of value in gastroenterology."

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.

For more information:

Visit our web site

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information